Subtopic Deep Dive

IL-23/IL-17 Axis in Psoriasis
Research Guide

What is IL-23/IL-17 Axis in Psoriasis?

The IL-23/IL-17 axis in psoriasis describes the pathway where dendritic cells produce IL-23 to drive Th17 and Tc17 T cell differentiation, leading to IL-17 secretion that triggers keratinocyte hyperproliferation and lesional inflammation.

IL-23, a heterodimeric cytokine of p19 and p40 subunits, promotes IL-17-producing T cells central to psoriasis pathogenesis (Langrish et al., 2005; 4011 citations). Mouse models using imiquimod confirm this axis mediates psoriasis-like inflammation (van der Fits et al., 2009; 2050 citations). Clinical trials of IL-17 inhibitors like secukinumab validate therapeutic targeting (Langley et al., 2014; 1917 citations).

Curated Papers

Key Challenges

Why It Matters

Targeting the IL-23/IL-17 axis with biologics like secukinumab achieves high PASI response rates in moderate-to-severe psoriasis patients (Langley et al., 2014). These inhibitors reduce lesional inflammation by blocking Th17 effector functions, improving quality of life and comorbidities like psoriatic arthritis (Armstrong and Read, 2020). Nestlé et al. (2009) highlight how axis dysregulation drives chronic plaques affecting 125 million worldwide, while Rendón and Schäkel (2019) note translation to effective therapies transforming treatment standards.

Key Research Challenges

Relapse After Biologic Blockade

IL-23/IL-17 inhibitors induce remission, but relapse mechanisms post-cessation remain unclear. Griffiths et al. (2021) report sustained efficacy challenges in long-term trials. Understanding rebound inflammation requires longitudinal studies (Armstrong and Read, 2020).

Th17 Heterogeneity in Lesions

Human Th17 cells show variable phenotypes beyond IL-17 production, complicating targeted therapies. Annunziato et al. (2007; 1827 citations) characterize distinct activation states. Integrating TC17 contributions adds complexity (Nestlé et al., 2009).

Keratinocyte Feedback Loops

IL-17 amplifies keratinocyte IL-23 production, sustaining inflammation cycles. Zheng et al. (2006; 1826 citations) link IL-22 to acanthosis via this axis. Dissecting feedback for combination therapies challenges current models (Rendón and Schäkel, 2019).

Essential Papers

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

Claire L. Langrish, Yi Chen, Wendy M. Blumenschein et al. · 2005 · The Journal of Experimental Medicine · 4.0K citations

Interleukin (IL)-23 is a heterodimeric cytokine composed of a unique p19 subunit, and a common p40 subunit shared with IL-12. IL-12 is important for the development of T helper (Th)1 cells that are...

Psoriasis

Frank O. Nestlé, Daniel H. Kaplan, Juliet N. Barker · 2009 · New England Journal of Medicine · 2.7K citations

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

Leslie van der Fits, Sabine Mourits, Jane S.A. Voerman et al. · 2009 · The Journal of Immunology · 2.0K citations

Abstract Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, a crucial role was...

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

April W. Armstrong, Charlotte Read · 2020 · JAMA · 2.0K citations

Importance Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic disease...

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · 2014 · New England Journal of Medicine · 1.9K citations

Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov num...

Psoriasis Pathogenesis and Treatment

Adriana Rendón, Knut Schäkel · 2019 · International Journal of Molecular Sciences · 1.9K citations

Research on psoriasis pathogenesis has largely increased knowledge on skin biology in general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis have been tr...

Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17

Sudeepta Aggarwal, Nico Ghilardi, Ming-Hong Xie et al. · 2003 · Journal of Biological Chemistry · 1.8K citations

Interleukin (IL)-17 is a pro-inflammatory cytokine that is produced by activated T cells. Despite increasing evidence that high levels of IL-17 are associated with several chronic inflammatory dise...

Reading Guide

Foundational Papers

Start with Langrish et al. (2005; 4011 citations) for IL-23 T cell pathology discovery, then Aggarwal et al. (2003; 1829 citations) for mechanistic links, and van der Fits et al. (2009; 2050 citations) for mouse model validation.

Recent Advances

Study Armstrong and Read (2020; 1992 citations) for clinical updates, Griffiths et al. (2021; 1981 citations) for pathogenesis synthesis, and Langley et al. (2014; 1917 citations) for secukinumab trial results.

Core Methods

Key techniques include imiquimod-induced mouse inflammation (van der Fits et al., 2009), Th17 phenotyping via flow cytometry (Annunziato et al., 2007), and phase 3 RCTs for biologics (Langley et al., 2014).

How PapersFlow Helps You Research IL-23/IL-17 Axis in Psoriasis

Discover & Search

Research Agent uses searchPapers('IL-23 IL-17 psoriasis axis') to retrieve Langrish et al. (2005; 4011 citations), then citationGraph reveals downstream works like van der Fits et al. (2009), and findSimilarPapers expands to Aggarwal et al. (2003) for Th17 origins.

Analyze & Verify

Analysis Agent applies readPaperContent on Langley et al. (2014) phase 3 trials, verifyResponse with CoVe checks efficacy claims against raw PASI data, and runPythonAnalysis computes meta-analysis of response rates using pandas on extracted trial stats; GRADE grading scores secukinumab evidence as high-quality.

Synthesize & Write

Synthesis Agent detects gaps in relapse mechanisms post-Langrish et al. (2005), flags contradictions between mouse models (van der Fits et al., 2009) and human trials; Writing Agent uses latexEditText for figure legends, latexSyncCitations integrates 10+ references, latexCompile generates review PDF, exportMermaid diagrams Th17 differentiation pathways.

Use Cases

"Extract cytokine levels from IL-23/IL-17 psoriasis trials and plot dose-response curves"

Research Agent → searchPapers → Analysis Agent → readPaperContent (Langley et al., 2014) → runPythonAnalysis (pandas/matplotlib plots IL-17 reduction vs. PASI75) → researcher gets publication-ready dose-response graph.

"Draft LaTeX review section on secukinumab efficacy with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText (structure abstract) → latexSyncCitations (add Langley et al., 2014; Griffiths et al., 2021) → latexCompile → researcher gets compiled PDF with synced bibliography.

"Find code for IL-23/IL-17 mouse model simulations"

Research Agent → searchPapers('imiquimod IL-23 model') → paperExtractUrls (van der Fits et al., 2009) → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python scripts for inflammation dynamics.

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'IL-23/IL-17 psoriasis', structures report with GRADE-scored evidence from Langrish et al. (2005) and Langley et al. (2014). DeepScan applies 7-step CoVe analysis to verify Th17 claims in Nestlé et al. (2009), outputting checkpoint-validated summary. Theorizer generates hypotheses on relapse from citationGraph linking Aggarwal et al. (2003) to recent trials.

Try Doxa for IL-23/IL-17 Axis in Psoriasis Research

Frequently Asked Questions

What defines the IL-23/IL-17 axis in psoriasis?

Dendritic cells secrete IL-23, driving Th17/Tc17 cells to produce IL-17, which induces keratinocyte responses fueling plaques (Langrish et al., 2005).

What methods validate this axis?

Imiquimod mouse models show IL-23/IL-17 dependence (van der Fits et al., 2009); secukinumab phase 3 trials confirm IL-17 blockade efficacy (Langley et al., 2014).

What are key papers?

Langrish et al. (2005; 4011 citations) establishes IL-23-driven pathology; Nestlé et al. (2009; 2693 citations) reviews psoriasis role; Aggarwal et al. (2003; 1829 citations) links IL-23 to IL-17.